Business Wire
21 Oct 2026, 21:44 UTC · 1h ago
Impact · against what's priced in
QIAGEN's preliminary Q3 2026 results show net sales of $548 million and adjusted EPS of $0.65. These figures provide a baseline for the upcoming full report on November 4 but lack qualitative context to drive a significant valuation shift.
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
What the story claims
2 claims · scored −1 bearish … +1 bullish · 2 new · 0 priced in
QIAGEN reported preliminary Q3 2026 net sales of $548 million at both reported and constant exchange rates.
Newannounced today
More positive than 68% of claims this week
Adjusted diluted earnings per share (EPS) for Q3 2026 were $0.65, also $0.65 on a constant exchange rate basis.
New
Continue reading
5 related stories
So whatActual EPS will be clarified alongside the full report on November 4.
More positive than 56% of claims this week
Which stocks this story touches
Near neutral — 91% of ticker scores this week are stronger
The article provides preliminary financial results without qualitative commentary indicating a positive or negative trend.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
2h ago
